Home › Compare › VTEPF vs ABBV
VTEPF yields 6309.15% · ABBV yields 3.06%● Live data
📍 VTEPF pulled ahead of the other in Year 1
Combined, VTEPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VTEPF + ABBV for your $10,000?
Videndum Plc designs, manufactures, and distributes products and services that enable end users to capture and share exceptional content for the broadcast, cinematic, video, photographic, and smartphone applications worldwide. It operates through three divisions: Imaging Solutions, Production Solutions, and Creative Solutions. The Imaging Solutions division offers equipment for photographic and video cameras, and smartphones; and solutions to professional and amateur photographers/videographers, independent content creators (ICCs), vloggers/influencers, gamers, enterprises, and professional sound crews comprising camera supports and heads, smartphone accessories, lighting supports, light-emitting diode (LED) lighting, lighting controls, motion controls, audio capture and noise reduction equipment, and camera bags and backgrounds. The Production Solutions division provides video heads, tripods, LED lighting, prompters, robotic camera systems, and mobile power solutions, as well as equipment rental and technical solutions for broadcasters, film and video production companies, ICCs, and enterprises. The Creative Solutions division offers wireless video transmission and lens control systems, monitors, camera accessories, live streaming and IP video devices, and software applications to ICCs, enterprises, gamers, broadcasters, and film and video production companies. The company was formerly known as The Vitec Group plc and changed its name to Videndum Plc in May 2022. Videndum Plc was founded in 1909 and is headquartered in Richmond, the United Kingdom.
Full VTEPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.